Citrus Bergamot: What the Clinical Research Actually Shows
Citrus bergamot has moved from Italian perfume factories to the shelves of American supplement aisles, usually marketed as a "natural statin." The editorial team reviewed the human data behind that claim: which outcomes were measured, how strong the trials are, and where the marketing gets ahead of the science.
What citrus bergamot is
Citrus bergamia is a citrus fruit grown almost exclusively along a narrow coastal strip of Calabria in southern Italy. Its peel oil has been used for centuries in fragrances and to flavor Earl Grey tea, but the juice was long considered too bitter to sell. That bitterness turned out to be the interesting part: the juice is unusually rich in flavonoids.
The main compounds of interest are naringin, neoeriocitrin and neohesperidin, plus two less common molecules called brutieridin and melitidin. The latter two carry a chemical group (3-hydroxy-3-methylglutaryl) that resembles part of the substrate of HMG-CoA reductase, the enzyme blocked by statin drugs. That structural similarity is the origin of the "natural statin" label.
Most clinical studies have used a standardized product called bergamot polyphenolic fraction (BPF), made by concentrating juice polyphenols. Supplements on the US market vary widely in how closely they match that research material, which matters when interpreting any claim on a label.
In the United States, bergamot extract is sold as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA). That means the FDA does not review efficacy before sale, and manufacturers may make structure/function claims such as "supports healthy cholesterol" but not disease-treatment claims.
Proposed mechanisms of action
Researchers have suggested several overlapping mechanisms, most of them derived from cell and animal studies. The first is partial inhibition of HMG-CoA reductase by brutieridin and melitidin, which would reduce the liver's own cholesterol production in a statin-like fashion, though far less potently.
The second is activation of AMP-activated protein kinase (AMPK), a cellular energy sensor. AMPK activation tends to shift metabolism away from fat synthesis and toward fat oxidation, which could explain reported effects on triglycerides and liver fat. Third, bergamot flavonoids have antioxidant properties that may reduce LDL oxidation, a step involved in plaque formation.
Finally, some studies have measured changes in LDL particle size, reporting a shift away from small, dense particles. Small dense LDL is considered more atherogenic, so this would be a meaningful effect if confirmed in larger, independent trials.
It is important to keep these mechanisms in proportion. A plausible pathway in a test tube does not guarantee a clinically relevant effect in people, and the concentration of active flavonoids reaching the liver after an oral dose is not well characterized.
What human trials report
The earliest human data came from an Italian group led by Vincenzo Mollace, which reported in 2011 that BPF reduced total cholesterol, LDL cholesterol and triglycerides and modestly raised HDL in people with elevated lipids. Follow-up work by the same group found that combining BPF with low-dose rosuvastatin produced greater LDL lowering than the statin alone.
A six-month prospective study by Toth and colleagues (2016) reported lower LDL, fewer small dense LDL particles and a small reduction in carotid intima-media thickness in adults with moderately elevated cholesterol. However, it was an open-label study without a placebo group, which limits how much weight it can carry.
A 2020 systematic review by Lamiquiz-Moneo and colleagues pooled the available human studies and concluded that bergamot appears to improve the lipid profile, but noted small sample sizes, short durations, heterogeneous products and a high proportion of trials from a single research network.
| Outcome | Direction reported | Strength of evidence |
|---|---|---|
| LDL cholesterol | Decrease | Moderate; mostly small trials |
| Triglycerides | Decrease | Moderate; inconsistent magnitude |
| HDL cholesterol | Small increase | Low |
| Fasting glucose | Possible decrease | Low |
| Heart attacks, strokes, mortality | Not studied | None |
The most important gap is in hard outcomes. Statins have been tested in trials with tens of thousands of participants that show fewer heart attacks and deaths. No study has shown that bergamot reduces cardiovascular events, so it cannot be considered an equivalent substitute.
Safety, interactions and quality
In published trials, bergamot extract has generally been well tolerated over periods of up to several months. Reported side effects are mild and include heartburn, stomach discomfort and occasional muscle cramps. Long-term safety data beyond a year are lacking.
Because the extract may act on cholesterol synthesis and liver enzymes, the theoretical interaction concerns include:
- Statins and other lipid drugs: additive effects are possible, which may be desirable under medical supervision but should not be improvised.
- Diabetes medications: if glucose-lowering effects are real, they could add to metformin, sulfonylureas or insulin.
- Drugs metabolized by CYP3A4: some citrus flavonoids, notably those in grapefruit, inhibit this enzyme; whether bergamot extract does so meaningfully is not established.
Bergamot essential oil is a different product. It contains bergapten, a furocoumarin that can make skin highly sensitive to sunlight. Oral juice extracts are typically processed to remove it, but this is one reason to choose products with transparent specifications.
Quality is a real concern in the US supplement market. Look for products that state the polyphenol content and carry third-party certification such as USP Verified or NSF, which confirm that the label matches the contents, though not that the product works.
Who might consider it, and who should not
Bergamot is most often discussed by people with borderline-high LDL or triglycerides who are not yet candidates for medication, and by people who cannot tolerate statins. Even in these groups, the starting point recommended by the 2018 AHA/ACC cholesterol guideline is lifestyle: diet quality, physical activity, weight management and not smoking.
Anyone with established cardiovascular disease, familial hypercholesterolemia, diabetes or a high calculated 10-year risk should not replace prescribed therapy with a supplement. For these people, the benefit of proven drugs is too large to gamble on an under-studied alternative.
Pregnant and breastfeeding women, children and people with liver disease were excluded from most trials, so safety in these groups is unknown. If you decide to try bergamot, the sensible approach is to measure a fasting lipid panel before and after two to three months, so the decision is based on your own numbers rather than marketing.
Athletes may also notice bergamot in "organ support" stacks. It is not a WADA-prohibited substance, but blended products carry contamination risk, so certified products are the safer choice for tested competitors.
Editorial team conclusions
Citrus bergamot is one of the more interesting botanical extracts for lipid health, with a plausible mechanism and several human studies reporting lower LDL and triglycerides.
The evidence, however, is still preliminary: trials are small, short, often uncontrolled and concentrated in a single research group, and no study has measured heart attacks or strokes.
It may be a reasonable adjunct for some people under medical supervision, but it is not a substitute for statins or other evidence-based therapy.
For related reading, see our articles on how to interpret a lipid panel, on red yeast rice and its regulatory history, and on omega-3 fatty acids and triglycerides.
References
- Mollace V, Sacco I, Janda E, et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia. 2011;82(3):309–316.
- Gliozzi M, Walker R, Muscoli S, et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Int J Cardiol. 2013;170(2):140–145.
- Toth PP, Patti AM, Nikolic D, et al. Bergamot reduces plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: a 6 months prospective study. Front Pharmacol. 2016;6:299.
- Lamiquiz-Moneo I, Giné-González J, Alisente S, et al. Effect of bergamot on lipid profile in humans: a systematic review. Crit Rev Food Sci Nutr. 2020;60(18):3133–3143.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082–e1143.
